Clinical Trials Logo

Clinical Trial Summary

The GUARD Trial is a multi-center, randomized, controlled, adaptive Phase 3 clinical trial of repeated intravitreal injections of ADX-2191 versus standard-of-care for the prevention of proliferative vitreoretinopathy.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04136366
Study type Interventional
Source Aldeyra Therapeutics, Inc.
Contact
Status Completed
Phase Phase 3
Start date November 15, 2019
Completion date June 14, 2022

See also
  Status Clinical Trial Phase
Recruiting NCT05561569 - Air Versus Gas Tamponade in Primary Retinal Detachment N/A
Not yet recruiting NCT05538156 - Internal Limiting Membrane Peeling in Retinal Detachment Surgery N/A
Completed NCT01445028 - Isotretinoin for Proliferative Vitreoretinopathy Phase 4
Recruiting NCT00370760 - Oral Colchicine Combined With Intravitreal Infusion of Dexamethasone, LMW Heparin and 5-FU for Management of Proliferative Vitreoretinopathy (PVR) Phase 3
Completed NCT00000140 - The Silicone Study Phase 3
Completed NCT06166914 - Efficacy of 5-fluorouracil and Low Molecular Weight Heparin in High-risk Pediatric Retinal Detachment N/A
Recruiting NCT04580147 - Intravitreal Aflibercept for the Prevention of Proliferative Vitreoretinopathy Following Retinal Detachment Repair Phase 2
Completed NCT04891991 - Intravitreal Infliximab for Proliferative Vitreoretinopathy Phase 2
Completed NCT01255293 - Comparative Study of 1000 Centistoke Versus 5000 Centistoke Silicone Oil for Repair of Complex Retinal Detachments N/A
Recruiting NCT06289205 - "Comparing Methotrexate Usage Techniques to Prevent Proliferative Vitreoretinopaty After Retinal Detachment Vitrectomy" Phase 1/Phase 2
Completed NCT00373282 - Triamcinolone Acetonide in Silicone-Filled Eyes as Adjunctive Treatment for Proliferative Vitreoretinopathy Phase 3
Completed NCT01995045 - Postoperative Pain Control Following Vitreoretinal Surgery Phase 4
Completed NCT04490876 - Outcomes of Extensive Brilliant Blue G-Assisted Internal Limiting Membrane Peeling in Proliferative Vitreoretinopathy
Completed NCT02192970 - Bevacizumab Against Recurrent Retinal Detachment Phase 2
Not yet recruiting NCT04682054 - Molecular Taxonomy of Surgically-harvested Ocular Tissues Defined by Single-cell Transcriptomics N/A
Recruiting NCT05660447 - A Multi-Center Study on the Use of Rho-Kinase Inhibitor to Reduce or Prevent PVR in RRD Eyes at High Risk for PVR Phase 2/Phase 3
Not yet recruiting NCT06033703 - Topical Netarsudil for the Prevention of Proliferative Vitreoretinopathy in Patients With Retinal Detachment Phase 1/Phase 2
Active, not recruiting NCT00371020 - The Effect of 5-FU and LMW Heparin on the Rate of Retinal Redetachment After Silicone Oil Removal in Cases of PVR Phase 3
Completed NCT03727776 - Adrenocorticotropic Hormone (ACTH) for Post-op Inflammation in Proliferative Vitreoretinopathy (PVR) Early Phase 1
Recruiting NCT04482543 - Repeated Methotrexate for Proliferative Vitreoretinopathy Grade C Phase 2/Phase 3